<a href="https://laohu8.com/S/ARTV">Artiva Biotherapeutics</a> reports Q3 2025 results with $123 million cash and investments
Artiva Biotherapeutics Inc. reported cash, cash equivalents, and investments of $123.0 million as of September 30, 2025, expected to fund operations into the second quarter of 2027. Research and development expenses were $17.6 million for the three months ended September 30, 2025, up from $13.5 million for the same period in 2024. General and administrative expenses totaled $5.3 million, compared to $4.8 million for the prior year period. Other income, net, was $1.4 million, compared to $0.9 million for the same period in 2024. During the quarter, Artiva announced a CFO transition and highlighted ongoing clinical trials, with initial clinical response data in refractory rheumatoid arthritis expected in the first half of 2026 and plans for FDA discussions regarding potential pivotal trial design.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573859-en) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.